NAGE — Niagen Bioscience Inc

Niagen Bioscience, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $33.8 million, up 16% year-over-year.
• Full Year Revenue: $129.4 million, reflecting a 30% increase year-over-year.
• Net Income: Q4 net income was $4.1 million; full-year net income totaled $17.4 million, compared to $8.6 million in 2024.
• Cash Position: Ended the year with $64.8 million in cash and no debt.
• Gross Margin: Q4 gross margin improved to 64.1%, up from 62.5% a year ago.
• Adjusted EBITDA: $20.4 million for the full year, an increase of $11.9 million compared to 2024.

2. Strategic Updates and Business Highlights

• Product Development: Launched Niagen Plus, with plans for at-home injection kits and expansion into beauty and cosmetics markets.
• Clinical Research: 29 studies published on nicotinamide riboside (NR), with significant findings on its benefits for fatigue and biological aging.
• Litigation: Initiated legal action against the FDA regarding the marketing status of NMN, which could impact competitive dynamics.
• Divestiture: Sold the ChromaDex Reference Standards business for $6 million, focusing resources on core NAD science.

3. Forward Guidance and Outlook

• 2026 Revenue Growth: Projected growth of 10% to 15%, excluding revenue from the divested Analytical Reference Standards segment.
• Gross Margin: Anticipated slight improvement due to supply chain efficiencies and product mix.
• Expense Projections: Selling and marketing expenses expected to increase in absolute terms but remain stable as a percentage of sales. R&D expenses to rise due to investments in pharmaceutical development.

4. Bad News, Challenges, or Points of Concern

• Increased Competition: Noted heightened competition in the NAD space, particularly from NMN products following FDA's reversal on its marketing status.
• Regulatory Risks: Ongoing litigation with the FDA poses uncertainties that could affect market dynamics and competitive positioning.
• Market Fluctuations: Anticipated fluctuations in sales from B2B partnerships, particularly with Watsons, which could impact revenue predictability.

5. Notable Q&A Insights

• Injection Product Launch: Initial launch will feature one SKU targeting the biohacker community, with plans for expansion based on market response.
• Conservative Guidance: Management emphasized a cautious approach to revenue guidance, preferring to under-promise and over-deliver.
• Marketing Strategy: Plans for a more aggressive brand awareness campaign in 2026, particularly if expanding into retail channels.
• Legal Expenses: Expected to be minimal for the FDA lawsuit, with a focus on a summary judgment approach.
• Future Clinical Research: Collaboration with Dr. Tzoulis on preventative applications of NR in Parkinson's disease is in the pipeline.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a balanced view of Niagen Bioscience's current position and future outlook.